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Abstract: The genome of Mycobacterium tuberculosis (Mtb) encodes three β-carbonic anhydrases (CAs,
EC 4.2.1.1) that are crucial for the life cycle of the bacterium. The Mtb β-CAs have been cloned and
characterized, and the catalytic activities of the enzymes have been studied. The crystal structures
of two of the enzymes have been resolved. In vitro inhibition studies have been conducted using
different classes of carbonic anhydrase inhibitors (CAIs). In vivo inhibition studies of pathogenic
bacteria containing β-CAs showed that β-CA inhibitors effectively inhibited the growth of pathogenic
bacteria. The in vitro and in vivo studies clearly demonstrated that β-CAs of not only mycobacterial
species, but also other pathogenic bacteria, can be targeted for developing novel antimycobacterial
agents for treating tuberculosis and other microbial infections that are resistant to existing drugs.
In this review, we present the molecular and structural data on three β-CAs of Mtb that will give
us better insights into the roles of these enzymes in pathogenic bacterial species. We also present
data from both in vitro inhibition studies using different classes of chemical compounds and in vivo
inhibition studies focusing on M. marinum, a model organism and close relative of Mtb.
Keywords: Mycobacterium tuberculosis; β-carbonic anhydrases; drug targets; tuberculosis; carbonic
anhydrase inhibitors; in vitro inhibition; antituberculosis drugs
1. Introduction
Diseases caused by Mycobacterium tuberculosis (Mtb) and other mycobacterial species affect a large
number of people in the world [1]. According to recent World Health Organization (WHO) estimates
approximately 10 million people developed TB disease in 2017 [2]. Worldwide, tuberculosis (TB) is one
of the top 10 causes of death and the leading cause of a single infectious agent. In 2017, TB disease
caused approximately 1.6 million deaths [2]. In addition, drug-resistant TB continues to be a public
health problem. The best estimate is that in 2017 558,000 people (range, 483,000–639,000) developed TB
that was resistant to rifampicin (RR-TB), the most effective first-line drug, and 82% of these cases had
multidrug-resistant TB (MDR-TB) [2].
The genome-sequencing project of Mtb [3] and other pathogenic bacteria including M.
marinum (Mmar), a model bacterium, have greatly increased our knowledge about the evolution
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of mycobacteria [4,5]. Sequencing of the genomes of pathogenic mycobacteria also helped us to identify
new drug targets, which might lead to the development of anti-TB drugs possessing a novel mechanism
of action and thus resolve the multidrug resistance (MDR) challenge of mycobacteria that has emerged
recently [3–7]. Among these targets, three novel proteins have been identified as carbonic anhydrases
(CAs, EC 4.2.1.1).
The CA enzymes are ubiquitous in nature and belong to eight different unrelated gene families
(α-, β-, γ-, δ-, ζ-, η-, θ-, and ι-CAs) [8,9] and are known to perform important physiologic roles in
living organisms [8–11]. The CAs of vertebrates belong to the α-CA gene family, which contains
multiple isoforms of the enzyme. CAs are involved in a fundamental reaction in which carbon
dioxide is reversibly hydrated to generate both bicarbonate and hydrogen ions for the regulation of
pH homeostasis. In addition, CAs participate in biosynthetic reactions, such as gluconeogenesis and
ureagenesis in mammals. Due to their association with various diseases, α-CA enzymes are considered
important targets for the design of new drugs, such as antidiuretics, antiglaucoma, antiepileptic,
and anticancer agents [11]. In the recent past, CAs belonging to the β-CA family have emerged as
potential targets for developing drugs against diseases caused by bacterial and parasitic pathogens.
Indeed, several in vitro inhibition studies have shown that the β-CAs from pathogenic bacteria and
parasitic pathogens can be inhibited by certain compounds [12–24]. Among these inhibitors are
sulfonamides and their bioisosteres, which are the main classes of CA inhibitors that have been in
clinical use for more than 50 years [25–28]. In addition, many studies have shown that pathogenic
organisms are susceptible to CA inhibitors in vivo as well [9,25,29–31].
Analysis of Mtb CA sequences has revealed that Mtb CAs belong to the β-CA gene family, are
encoded by genes Rv1284, Rv3588c, and Rv3273, and are denoted as β-CA1, β-CA2, and β-CA3,
respectively [3,9,32]. The Mtb β-CAs are zinc-containing metalloenzymes with characteristics similar to
those of many other bacterial β-CAs, including all the conserved amino acid residues involved in the
catalytic cycle, i.e., the four zinc-binding residues Cys42, Asp44, His97, and Cys101 [9]. The three Mtb
β-CAs have been cloned and purified, and kinetic studies of these CAs have been carried out [33–37].
The X-ray crystal structures of two of the Mtb β-CAs (Rv1284 and Rv3588c) have been resolved [36,37].
Studies conducted on mycobacterial β-CAs have shown that they are involved in the invasion and
survival of pathogens in the host environment and are thus considered potential drug targets for
developing novel anti-TB agents [9]. Several in vitro inhibition studies have shown that Mtb β-CAs can
be efficiently inhibited by different classes of inhibitors [9]. In this review, we present the molecular
data on the gene and protein sequences as well as the information on 3D structures of Mtb β-CAs
that is available in the literature. We also review the available data on the roles of β-CAs in Mtb and
nontuberculous mycobacteria (NTM), which include information on Mmar, a model organism for
studying the physiological roles of β-CAs in mycobacteria and a close relative of Mtb. Similarly, we also
discuss the data from in vitro inhibition studies using different classes of chemical compounds.
2. Molecular Biology
The β-CA genes of Mtb (Rv1284, Rv3588c, and Rv3273) have been cloned, recombinant proteins
of these CAs have been produced, and activity and inhibition studies have been carried out [34–37].
The X-ray crystal structures of two of the enzymes (Mtb β-CA1 and Mtb β-CA2) have been
resolved [36,37]. The details of the molecular characterization of the Mtb β-CA genes are presented in
the following sections.
2.1. M. tuberculosis Rv1284
The gene Rv1284 encodes Mtb β-CA1, and the length of the corresponding peptide is 163 amino
acid residues (Figure 1). The protein product of Rv1284 was identified in the membrane fraction of
Mtb strain H37Rv by SDS-PAGE [38] and uLC-MS/MS [39]. The mRNA transcript is upregulated after
4 and 24 h of starvation, and the upregulation is highest at 96 h [40]. The gene product is required for
the growth of bacteria in the C57BL/6J mouse spleen detected by transposon site hybridization (TraSH)
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in H37Rv [41]. The Mtb Rv3588c gene was cloned, and the crystal structure of the corresponding
recombinant protein was studied in 2005 by Suarez Covarrubias et al. [36]. In a later report in
2009, kinetic studies of the recombinant enzyme were carried out by Minakuchi et al. (Table 1) [34].
The analysis of the cloned sequence showed no differences to the original sequence available in the
UniProt database [3,34].
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Table 1. Activity and inhibit on kineti tb β-CAs compared to human CA II.
CAs Gene ID Protein Kcat (S−1) Kcat/Km (M−1S−1) KI (nM) a Ref.
Mtb β-CA1 Rv1284 163 aa 3.9 × 105 3.7 × 107 480 [34]
Mtb β-CA2 Rv3588c 207 aa 9.8 × 105 9.3 × 107 9.8 [35]
Mtb β-CA3 Rv3273 764 aa b 4.3 × 105 4.0 × 107 104 [33]
hCA II CA2 260 aa 1.4 × 106 .5 × 108 12 [35]
a Inhibition using acetazolamide; b Sulfate transporter domain (amino acids 121–414).
Interestingly,Mtb β-CA1 is a smaller protein compared to other β-CA enzymes and more specifically
compared to the β-CA2 enzyme of mycobacteria [34]. In β-CA1 the Zn(II) ion is coordinated by an
aspartate residue, possessing a so-called ‘closed’ active site conformation, which is also observed in
some algal β-CA enzymes [34]. It has also been shown that many amino acids are different in β-CA1
compared to β-CA2, suggesting a structural bas s for the difference in catalytic activ ty nd affinity
to CA inhibitors, as shown in Ta le 1 [34]. Interestingly, a study carr ed out in 2015 by Hofmann’s
group showed that Rv1284 is susceptible to redox conditions in the host envir ment, li king oxidative
stimuli to changes in the pH homeostasis of the pathogen [42]. The inactivation of Rv1284 due
to oxidation stops the enzymatic hydration of carbon dioxide and thus the production of protons;
therefore, the decrease in the pH within the vicinity of action of Rv1284 could be a strategy employed
by mycobacteria for survival in the host [42].
2.2. M. tuberculosis Rv3588c
The protein encoded by gene Rv3588c, also known in the databases as CanB, is a β-CA and
contains 207 amino acid residues (Figure 2) [36]. Biochemical experiments have shown that the protein
product of Rv3588c is similar to the putative 213 aa CA Q9CBJ1 of Mycobacterium leprae [36]. The protein
was identified by mass spectrometry in the membr ne protein fraction of Mtb H37Rv [43] a d the
proteomic data supported the translation start site [44]. Transposon hybridization (TraSH) assay in
H37Rv showed that the gene is required for bacterial growth in C57BL/6J mouse spleen [41].
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The available data from sequence alignment and from crystallographic studies have shown that
Mtb β-CA2 has zinc ligands that are present in other bacterial β-CAs [35]. Kinetic studies have shown
that the product of the Rv3588c gene of Mtb possesses the highest catalytic activity for CO2 hydration
among the three Mtb β-CAs (Table 1) [35].
2.3. M. tuberculosis Rv3273
The Rv3273 gene encoding β-CA3 was identified in 2002 from the genome of Mtb strain H37Rv [45].
It is believed to be a transmembrane protein based on its hydrophobic N-terminus [38,46,47]. Based on
the information fr m UniProt a d NCBI gene databases, the Rv3273 protein product is predicted to
contain 764 amino acids [3,45]. It is a bifunctional protein with a sulfate transporter domain at the
N-terminal end (amino acids 121–414) and a β-CA domain (amino acids 571–741) [33]. The schematic
structure of the protein product is shown in Figure 3. The domain organization of the protein is shown
to be similar to that of the other bacterial proteins found in Arthrobacter aurescens (YP_949116), Leptospira
borgpetersenii (YP_798800), Legionella pneumophila (YP_126096), and Leptospira interrogans (NP_710760),
which are putative bifunctional proteins and contain both sulfate transporter and β-CA domains [45].
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Figure 3. Schematic presentation of Mtb β-CA3 (Rv3273). (A) The complete β-CA3 protein showing
both the sulfate transporter and CA domains at the N- and C-terminal ends, respectively. (B) The
recombinant Mtb β-CA3 protein produced for kinetic studies [33].
The β-CA domain (amino acids 550–764) of the Rv3273 gene was cloned, characterized, and
denominated as β-CA3 [33]. The amino acid sequence of the cloned DNA was shown to be similar
to the amino acid sequence of Rv3273 that is available in databases [3,45] with the exception of a
substitution of amino acid Arg606 to Cys. Mtb β-CA3 has three conserved zinc binding residues
present in the β-CA1 and β-CA2 of Mtb [34,36,37], which are Cys584, His642, and probably Asp586 [33].
Activity and inhibition studies of β-CA3 have also been carried out, and the details of the kinetics are
shown in Table 1.
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3. M. marinum Is a Suitable Model for Studying the Roles of β-CAs
M. marinum, an NTM, is found in water and is a natural TB pathogen of zebrafish [4]. The Mmar
bacillus has several characteristics, such as slow growth, immotility, no spores, and Gram-positive
staining. Mmar is of great scientific interest because it is genetically related to Mtb, a pathogen
that causes TB in humans, and interestingly, the experimental infection of Mmar in fish mimics
the pathogenesis of TB [48]. The genome of the M strain of Mmar contains a 6,636,827-bp circular
chromosome. Mmar is widely used as a model organism to study TB, and genome comparisons have
confirmed the close genetic relationship between these two species showing that they share 3000
orthologs with an average amino acid identity of 85% [4].
Sequence and Phylogenetic Analysis of β-CAs
Bioinformatic studies of different Mmar strains showed the presence of three β-CAs in the
bacterium [29]. Analysis of Mmar β-CA sequences showed that they are closely related to the Mtb β-CA
sequences [29]. Sequence alignment of β-CA protein sequences from both organisms showed very
high conservation of amino acids between the sequences (identities for β-CA1: 85.2%, β-CA2: 86.8%,
and β-CA3: 72.8%). The names, numbering and sequences of the β-CAs were based on the UniProt
entries (Figure 4).
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Figure 4. Alignment of the Mtb and Mmar β-CA protein sequences. Conserved amino acid residues
between the three Mtb CAs (UniProt IDs: Rv1284/CA1, Rv3588c/CA2, and Rv3273/C 3) and the
corresponding Mmar β-CA sequences are indicated by asteri ks. (A) Shows the alignment of β-CA1
sequences of Mtb and Mmar; (B) Shows the alignment of β-CA2 sequences of Mtb and Mmar; and (C)
shows the alignment of β-CA3 sequences of Mtb and Mmar. The boxed yellow and blue highlighted
parts show the N-terminal sulfate transporter and C-terminal CA domains, respectively.
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Phylogenetic analysis showed that each of the three Mmar β-CAs are more closely related to the
correspondingMtb β-CA compared to the β-CA of other mycobacterial species (Figure 5A). A subcellular
localization prediction using a web-based tool [49] (and the information accessed from the TubercuList
(http://tuberculist.epfl.ch) database suggested that Mtb β-CA1 and β-CA2 are cytoplasmic (data not
shown), Mtb β-CA3 is a membrane-associated protein (Figure 5B), and these predicted localizations
match those of the Mmar β-CAs (Figure 5C) [49].
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Figure 5. Phylogeny of mycobacterial β-CA sequences and transmembrane domain prediction of
Mtb and Mmar β-CA3 protein sequences. The phylogenetic tree in panel (A) shows the evolutionary
relationship of the Mtb and Mmar β-CA protein sequences in comparison with β-CAs from other
organisms (Phatc = Phaeodactylum tricornutum; Babo = Brucella abortus; Tspi = Trichinella spiralis;
Dmel = Drosophila melanogaster; Mpor = Mycolicibacterium porcinum; and Ehis = Entamoeba histolytica).
Panel (B) shows the predicted transmembrane plot of Mtb β-CA3, and panel (C) shows the predicted
transmembrane plot of Mmar β-CA3 [49].
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4. Structures of Mtb β-CAs
The X-ray crystal structures of the two Mtb β-CAs have been resolved [36,37]. The Protein Data
Bank (PDB) contains the X-ray structures of two out of the three Mtb β-CAs: Rv1284 (PDB IDs 1YLK,
4YF4, 4YF5, and 4YF6) and Rv3588c (PDB IDs 1YM3 and 2A5V). The structure of the catalytic domain
of Rv3273 is available as a homology model in SWISS-MODEL Repository [50]. The latter structure was
generated by the automated SWISS-MODEL homology modeling pipeline based on β-CA Can2 from a
Cryptococcus neoformans template (2W3N, 26.3% identity). The structures of Mtb β-CAs are shown in
Figure 6. The catalytic domains of the three Mtb β-CAs possess the same β/α fold, which is unique
to the β-CAs [51]; therefore, their secondary structures share many similarities, as shown in Figure 6.
The most important catalytic property of the protein is the difference in the environment around the
zinc in the active site. The active sites of β-CAs are classified into ‘active’ or ‘open’ and ‘inactive’ or
‘closed’ conformations depending on the coordination of the zinc ion [51]. Mtb Rv3588c was shown to
switch between active and inactive conformations depending on the pH [37]; presumably the same
could also hold true for the other two Mtb β-CAs. The environment of the zinc center of each of the
Mtb β-CAs is shown in Figure 7. The active and inactive forms of β-CAs are characterized by different
conformations of the Asp side chain in the active site. In the inactive form, Asp is directly coordinated
to the Zn ion (Figure 7B). In the active form, Asp forms a salt bridge with a nearby Arg side chain
(Figure 7A,C,D). In addition, this conformation is further stabilized by a hydrogen bond from the Asp
carboxy group to the Arg backbone amide (also shown in Figure 7A, C, D). As shown in Figure 7,
the switch between the two β-CA forms is accompanied by both an Asp side chain rotation and by
a movement of the backbone on which the Asp is located. By coordinating to Zn, this residue acts
as an autoinhibiting agent by not allowing water molecules to bind to zinc (cf. Figure 7B,C) thus
preventing the catalytic activity. It should also be noted that the enzyme activity can be affected by
environmental redox conditions leading to a chemical modification of the active site, as shown by
applying redox agents to Rv1284 [42]. Oxidative conditions result in the removal of cysteine Cys35
(Figure 7A) from the Zn coordination sphere by forming a disulfide bond between Cys35 and a more
remotely positioned Cys61 (not shown), which could even lead to the loss of zinc ions. It was also
shown that the Tyr120 residue may be critical in the oxidative inactivation of Rv1284 [42]. Notably, in
Rv3588c and Rv3273, there is no Cys in the homologous position of Cys61, implying a higher resistance
to oxidative stress in these two Mtb β-CAs [42].
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Rv3588c, PDB ID: 1YM3, (C) closed conformation of Rv3588c, PDB ID: 2A5V, (D) homology model of
Rv3273 [36,37]. Zinc is shown as a gray sphere. In the inactive conformation, Asp in the binding site
ligates to Zn, and in the active conformation, Asp forms a salt bridge with Arg and a hydrogen bond
with the Arg backbone N. The zinc coordination bonds are shown as dashed lines, and the hydrogen
bonds between Asp and Arg are shown as green lines. In the active form, Zn is ligated to either water
(A) or other ligands (B–D).
5. Expression Analysis of β-CAs from Mmar
Expression analysis of the three β-CA g nes w s carried out in the Mmar ATCC 927 strai using
PCR, and the presence of transcripts was seen as bands of 500 bp for β-CA1, 490 bp for β-CA2, and
600 bp for β-CA3 (Figure 8A) [29]. Similarly, quantitative expression analysis of the β-CA genes in
different strains of Mmar (M, ATCC 927 and E11) was also performed using RT-qPCR, and the highest
expression was found in the ATCC 927 strain compared to the M and E11 strains. The molecular
analysis thus confirmed the presence of all three β-CA genes in Mmar (Figure 8).
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Figure 8. Expression analysis of β-CAs from Mmar: (A) The qualitative expression analysis of Mmar
β-CA genes showed the presence of all three β-CAs in the ATCC 927 strain. Genomic DNA was used as
a positive control. (B–D) Relative expression analysis of three β-CA genes from the three strains of
Mmar using RT-qPCR [29].
Int. J. Mol. Sci. 2019, 20, 5153 9 of 16
6. In Vitro Inhibition of Mycobacterial β-CAs
6.1. Inhibition of Mtb β-CAs Using Sulfonamides and Their Derivatives
The inhibition studies on Mtb β-CA1 were performed using a panel of sulfonamides, sulfamates,
and their derivatives, some of which are in clinical use [34]. Most of the tested compounds
showed high affinity for β-CA1 (inhibition range of 1–10 µM). The compounds with inhibition in the
submicromolar concentration range (KI values of 0.481-0.905 µM) included sulfanilyl-sulfonamides,
such as acetazolamide, methazolamide, dichlorophenamide, dorzolamide, brinzolamide, benzolamide,
and the sulfamate topiramate [34]. The most efficient inhibitors (KI values of 97–186 nM) of this enzyme
were 3-bromosulfanilamide and indisulam. The promising inhibition profiles of sulfonamides and
their derivatives used in this study suggested that the Mtb β-CA1 enzyme is a potential target for
developing anti-TB agents with a different mechanism of action [34].
Similarly, the inhibition profiles of a series of diazenylbenzenesulfonamides derived from
sulfanilamide or metanilamide were shown to inhibit Mtb β-CA2 in the range of 45–955 nM [52].
Subsequently, to obtain inhibitory molecules with better inhibition properties, new compounds were
synthesized by diazotization of aminosulfonamide and by coupling with phenols or amines [35].
These molecules were subsequently incorporated with various R moieties in the molecule—such as
hydroxy, amino, methylamino, dimethylamino, and sulfonate—which could induce water solubility of
these compounds as sodium salts. Among the molecules thus prepared, the aminomethylene sodium
sulfonate derivatives and their corresponding N-methylated analogues showed the most efficient
inhibition properties (KIs of 45–59 nM) [35]. Later, the diazenylbenzenesulfonamides were also tested
for the inhibition of Mtb β-CA3, and among them, prontosil was found to be the best inhibitor (KI
126–148 nM) [53]. In another study, several compounds were tested for their inhibition efficiency
against Mtb β-CA3. Compounds that inhibited the activity of this enzyme in the nanomolar range
included 2-amino-pyrimidin-4-yl-sulfanilamide (KI 90 nM) and sulfonylated sulfonamide (KI of 170
nM). These studies suggested that Mtb β-CA3 could be targeted using CAIs with the potential to
develop agents that target Mtb [33].
The sulfonamides prepared by reaction of sulfanilamide with aryl/alkyl isocyanates showed
inhibition of Mtb β-CA1 and β-CA3 in the range of 4.8–6500 nM and 6.4–6850 nM, respectively.
The structural activity relationship related to inhibition has been shown to be associated with the
nature of the moiety substituting the second ureido nitrogen, and it is the determining factor in
controlling the inhibitory power. This may be due to flexibility of the ureido linker and the ability
of this moiety to orientate in different subpockets of the active site cavities of these enzymes [54].
The inhibition of all three Mtb β-CAs using a number of halogenated sulfanilamides and halogenated
benzolamide derivatives showed inhibition efficiency in the submicromolar to micromolar range.
The substitution pattern at the sulfanilamide moiety/fragment of the molecule is crucial for the
inhibition efficiency of the molecule. The best inhibitors were the halogenated benzolamides (KIs in
the range of 0.12–0.45 µM), whereas the halogenated sulfanilamides were slightly less inhibitory (KIs
in the range of 0.41–4.74 µM) [55]. Similarly, the inhibition of the three Mtb β-CAs was carried out
using a series of fluorine-containing sulfonamides that were modified with amino, amino alcohol,
and amino acid moieties [56]. Among these, some showed efficient inhibition of β-CA2 (KI values
in the nanomolar range) and moderate inhibition efficiency against β-CA1 and β-CA3 (KI in the
low micromolar range) [56]. Recently, a novel sulfonamide molecule obtained from sulfanilamide,
which was N4-alkylated with ethyl bromoacetate followed by a reaction with hydrazine hydrate and
further reacted with various aromatic aldehydes, showed KIs in the range of 127 nM–2.12 µM for Mtb
β-CA3 [57].
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6.2. Mono and Dithiocarbamates as Inhibitors of Mycobacterial β-CAs
Studies have shown that both mono-(MTCs) and dithiocarbamates (DTCs) selectively inhibit
Mtb β-CAs. The inhibition of Mtb β-CA1 and β-CA3 using a series of N-MTCs and N,N-disubstituted
DTCs showed inhibition efficiencies in the subnanomolar to the micromolar range [58]. The inhibition
properties of these compounds were dependent on the substitution pattern at the nitrogen atom of
the DTC zinc-binding group. Replacement with aryl, arylalkyl-, heterocyclic as well as aliphatic
and aminoacyl moieties led to potent β-CA1 and β-CA2 inhibitors in both the N-mono-and
N,N-di-substituted DTC series [58].
6.3. Phenolic Natural Products and Phenolic Acids as Mycobacterial β-CA Inhibitors
In search of novel inhibitors that could selectively inhibit Mtb β-CAs, a series of phenolic natural
products (NPs) were screened against Mtb β-CA1 and Mtb β-CA3. It was shown that NPs were able to
selectively inhibit Mtb β-CA1 and β-CA3 with KIs in the submicromolar range [59]. Similarly, screening
of a series of phenolic acids and their derivatives against all three Mtb β-CAs showed good inhibition
efficiencies (KIs 1.87 µM–6.09 µM). In addition, these compounds showed no inhibitory activity against
human CA I or CA II, suggesting that the phenolic compounds could potentially be developed as
anti-TB agents [60]. Computational analysis of the binding mode of the compounds suggested that
the inhibitors anchored to the zinc-coordinated water molecule in the CA active site and interfered
with the nucleophilic attack of the zinc hydroxide on the substrate CO2 [60]. Screening of a series of
C-cinnamoyl glycosides containing the phenol moiety against the three Mtb β-CAs also showed that
most of the compounds were highly efficient inhibitors of Mtb β-CA2 (KI 130–940 nM), showing a
preference for β-CA2 over human CA II [61].
6.4. Carboxylic Acids as Inhibitors of Mycobacterial β-CA
Carboxylic acids are known to inhibit Mtb β-CAs, but the inhibitory mechanism of these acids is
not known. Screening of scaffolds containing carboxylic acids, such as benzoic acid, nipecotic acid,
ortho and para coumaric acid and ferulic acid, against all three Mtb β-CAs showed inhibition efficacy
in the micromolar range (KI 0.11–0.97 µM). The KIs for the inhibition of β-CA2 were in the range of
0.59–8.10 µM, whereas against β-CA1, the carboxylic acids showed inhibition constants in the range of
2.25–7.13 µM [62]. This class of inhibitors has not been well explored, and further in vitro inhibition
studies are needed to document the real potential of these inhibitors as anti-TB agents.
7. Inhibition of Mycobacterial Strains in Culture
In addition to studies on the in vitro inhibition of Mtb β-CAs, CA inhibitors have been used for the
inhibition of Mtb growth in culture [9]. Studies using 6-mercaptopurine with sulfony/sulfenyl halides
known as 9-sulfonylated/sulfenylated-6-mercaptopurines showed that the compounds inhibited growth
of the wild-type Mtb bacilli H37Rv in the range of 0.39–3.39 µg/mL [63]. Among these compounds,
one of the derivatives showed a minimal inhibitory concentration (MIC) of approximately 1 mg/mL
against several drug-resistant Mtb strains [63]. The compounds with MICs below 1 µg/mL were
considered excellent leads [63].
The inhibition of Mmar, a model mycobacterium, was recently investigated in liquid cultures using
DTCs Fc14-584a and Fc14-584a. The DTCs were prepared by the reaction of a corresponding amine with
carbon disulfide in the presence of a base. The obtained compounds were shown to be specific inhibitors
of Mtb β-CA1 and β-CA3 [58]. This study showed that the minimum concentration (MIC) required for
complete inhibition of Mmar was 75 µM. Further studies using the concentration below MIC (dilution
1:4) have shown no growth of Mmar, suggesting that the DTCs are bactericidal [29]. These studies
demonstrate that CAIs, in addition to inhibiting the activity of mycobacterial β-CAs, impair the growth
of both Mtb and NTM in culture and have significant potential as antimycobacterial compounds.
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8. In Vivo Inhibition of Mycobacteria by CA Inhibitors
In vivo studies have shown that 6-ethoxy-1,3-benzathiazole-2-sulfonamide (ETZ) impairs the
signaling of PhoPR in Mtb [64,65]. ETZ is a sulfonamide compound that is a general inhibitor of CA
activity and is an FDA-approved drug used in the treatment of glaucoma, epilepsy, and duodenal
ulcers and is also a diuretic [9]. ETZ treatment of Mtb induces phenotypes similar to the PhoPR
mutants downregulating the PhoPR regulon, a reduction in virulence-associated lipids, and inhibition
of Esx-1 protein secretion [64] (Table 2). Further studies on single-cell imaging of a PhoPR-dependent
fluorescent reporter strain showed that ETZ inhibited PhoPR-regulated genes in infected macrophages
and in mouse lungs [64]. A mouse model infected with bacteria containing a fluorescent reporter
showed a reduction in bacteria in the lungs and significantly reduced GFP fluorescence compared to
the control group [64].
The extracellular DNA (eDNA) in NTM is responsible for the phenotypic resistance of the bacteria
to antibiotics and plays an important biological role in the bacteria [66]. Studies have shown that
bicarbonate ion helps in the export of eDNA in NTM, and it is well established that the enzymatic activity
of CAs is involved in the production of bicarbonate ions via the hydration of carbon dioxide [11,67].
Furthermore, it has been demonstrated that a mutant M. avium in which CA genes were inactivated was
unable to export eDNA [67]. However, when the CA genes were restored, the transport of eDNA was
also restored, suggesting that CAs play important roles in the transport of eDNA and the formation of
biofilms by the bacteria [67] (Table 2). The surface-exposed proteome of M. avium in eDNA-containing
biofilms showed that CAs are abundantly present, and the inhibition studies showed a significant
reduction in eDNA transport in the presence of ETZ [67].
Table 2. In vivo inhibition studies showing the effects of CA inhibitors.
CA Inhibitor Mycobacterium Group Effect on the Bacterium References
Ethoxzolamide Mtb MTC Inhibits PhoPR regulon,attenuates virulence [64]
Ethoxzolamide M. avium NTM Reduces the transport of eDNAand biofilm formation [67]
Dithiocarbamate Mmar NTM Impairs growth of Mmar inzebrafish larvae [29]
DTCs, another class of compounds that strongly inhibit Mtb β-CAs in vitro, have been used in vivo
for the inhibition of Mmar [29,58]. The in vivo studies have shown that a DTC, FC14-384b (Figure 9B
and Table 2), significantly impaired the growth of Mmar in zebrafish larvae [29]. The zebrafish larvae
infected with the Mmar wasabi strain with an infection dose of 471 ± 143 (CFUs) bacteria and treated
with 300 µM FC14-384b showed a significant reduction (p > 0.0096) in bacterial load (Figure 9B)
compared to the zebrafish larvae not treated with the inhibitor (Figure 9A). These studies suggest
that the compounds that selectively inhibit the activity of β-CAs could be useful as a new class of
antimycobacterial agents that can potentially treat MDR-TB.
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The experimental data on the biochemical and molecular characterization of Mtb β-CAs have 
provided us with better insights into the diverse roles of these enzymes in the Mtb pathogen. In 
addition to their role in the hydration of CO2 required for pH homeostasis in the pathogen, these 
enzymes have been implicated in several nonenzymatic functions that are required for the survival 
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a clinically used drug, inhibits the secretion of virulence factors and attenuates Mtb. These findings 
represent an in vivo proof of concept that the Mtb β-CA enzymes are indeed promising targets for 
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only selective against the mycobacterial β-CAs but are also membrane permeable and safe for clinical 
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9. Conclusions
The experimental data on the biochemical and molecular characterization of Mtb β-CAs have
provided us with better insights into the diverse roles of these enzymes in the Mtb pathogen. In addition
to their role in the hydration of CO2 required for pH homeostasis in the pathogen, these enzymes
have been implicated in several nonenzymatic functions that are required for the survival f Mtb and
pathogenesis of TB disease in the host. How ver, precise phys ological roles of the individual enzymes
have yet to be discovered. In vitro inhibition studies using different classes of inhibitors have shown
that Mtb β-CAs are druggable targets with potential as anti-TB agents with a diverse mechanism of
action compared to the drugs that are in clinical use and to which the Mtb strains have developed
various degrees of resistance.
Interestingly, recent studies have shown that CA inhibitors that selectively inhibit Mtb β-CAs
in vitro also inhibit the growth of Mmar in vivo in zebrafish. Similarly, ETZ, a general CA inhibitor and
a clinically used drug, inhibits the secretion of virulence factors and attenuates Mtb. These findings
represent an in vivo proof of concept that the Mtb β-CA enzymes are indeed promising targets for
developi g antimycobacterial agents. However, we need to design novel CA inhibitors that are not
only selective against the mycobacterial β-CAs but are also membrane permeable and safe for clinical
use in humans when tested in strict preclinical and clinical settings.
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Abbreviations
The following abbreviations are used in this manuscript:
CA Carbonic anhydrase
Mtb Mycobacterium tuberculosis
Mmar Mycobacterium marinum
CAI Carbonic anhydrase inhibitor
MDR-TB Multidrug-resistant tuberculosis
WHO World Health Organization
TB Tuberculosis
MTBC Mycobacterium tuberculosis complex
NTM Nontuberculous mycobacteria
ETZ Ethoxzolamide
β-CA1 Beta-carbonic anhydrase 1
β-CA2 Beta-carbonic anhydrase 2
β-CA3 Beta-carbonic anhydrase 3
RR-TB Resistant to rifampicin Mycobacterium tuberculosis
eDNA Extracellular DNA
PDB Protein Data Bank
MTC Monothiocarbamates
DTC Dithiocarbamates
NP Natural products
MIC Minimal inhibitory concentration
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